Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Bayer said the FDA approved Kerendia (finerenone) to treat adult patients with chronic kidney disease associated with type 1 diabetes, its third approved indication in the U.S.
Bayer said the FDA approved KERENDIA (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) and type 1 diabetes, with the therapy expected to reduce the risk of sustained eGFR decline and end-stage kidney disease.